Back to results
US 2025/0199014 A1Published application
Metabolite biomarkers for diseases associated with the contact activation system
AssigneeTakeda Pharmaceutical Company Limited
InventorsDaniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Claims21
1-39. (canceled)
A method for analyzing a sample, comprising:
- (i) providing a biological sample from a subject having been administered a treatment for a disease associated with the contact activation system;
- (ii) measuring the level of a metabolite biomarker set, wherein the metabolite biomarker set comprises serotonin;
- (iii) assessing the efficacy of the treatment based on the level of the metabolite biomarker set, a deviation of the metabolite biomarker set level in the biological sample from that of a reference sample being indicative of the treatment efficacy.
The method of clam 40, wherein the metabolite biomarker set further comprises:
- (a) a metabolite biomarker associated with fatty acid amide hydrolase activity;
- (b) a lipid peroxide;
- (c) a metabolite involved in sulfur metabolism;
- (d) a metabolite involved in steroid metabolism;
- (e) a fatty acid;
- and/or
- (f) a cofactor precursor.
4 more elements
Dependencies are inferred from the claim text.